Moderna's $140 million investment in Norwood, Massachusetts, aims to complete its U.S. manufacturing loop, enhancing self-sufficiency and efficiency in drug production. The expansion will create ...

Just a few weeks after the company announced licensing agreements with Empirico and Syndivia, GSK announced a strategic collaboration with LTZ Therapeutics, advancing novel myeloid cell engagers in ...

This series kicks off by introducing David Edelman, Founder & CEO of Thrivable, who joins Pharmaceutical Executive to discuss the rising “clarity gap” that is currently putting pharma leaders under ...

David Edelman, Founder & CEO of Thrivable, provides an unflinching look at why today’s most relied-upon tools, including syndicated data, social listening, gut instinct, still leave leaders navigating ...

Understand how real-time patient intelligence transforms leadership conversations from speculation and opinion battles into confident, data-backed strategy.

Learn how outdated or incomplete insights turn every decision into a high-stakes gamble that cost brands money, momentum, and internal alignment.

Discover how AI-powered patient intelligence is ushering in a new era of pharma leadership defined by clarity, speed, and knowing the “why” behind every shift.

This episode acts as a peek inside the modern pharma boardroom, where leaders are expected to defend billion-dollar brands with data that’s too slow, too vague, and too outdated to survive today’s ...

Alkermes’ $1.50 CVR price is contingent upon approval for Avadel’s leading treatment candidate for idiopathic hypersomnia in adults, Lumryz, The treatment needs to receive approval by the end of 2028 ...

The first wave of Commissioner’s National Priority Vouchers signals a fundamental shift in FDA competitiveness, rewarding companies that pair breakthrough science with affordability commitments, ...

AbbVie and Genmab have received FDA approval for Epkinly as a treatment option for patients with relapsed or refractory follicular lymphoma. The decision adds a new targeted immunotherapy to the ...